Summary
Becton, Dickinson and Company (BDX) reported significant growth in fiscal year 2015, largely driven by the transformative acquisition of CareFusion in March 2015. This acquisition positioned BD as a leader in medication management and patient safety solutions. Despite a substantial increase in debt to fund the CareFusion deal, the company demonstrated revenue growth across both its Medical and Life Sciences segments, with the Medical segment showing particular strength due to the inclusion of CareFusion's operations. While the company faced increased interest expenses and integration costs related to the acquisition, its strategic focus on innovation, emerging markets, and operational efficiency remains. Investors should note the impact of acquisition-related costs and purchase accounting adjustments on the current year's profitability, which obscured the underlying operational performance. The company's commitment to returning shareholder value through dividends was maintained, though share repurchases were suspended to manage debt levels post-acquisition. Overall, the report signals a strategic shift with the CareFusion integration being the primary focus, aiming for long-term growth and market leadership.
Financial Highlights
57 data points| Revenue | $10.28B |
| Cost of Revenue | $5.59B |
| Gross Profit | $4.70B |
| R&D Expenses | $632.00M |
| SG&A Expenses | $2.56B |
| Operating Expenses | $9.21B |
| Operating Income | $1.07B |
| Interest Expense | $371.00M |
| Net Income | $695.00M |
| EPS (Basic) | $3.43 |
| EPS (Diluted) | $3.35 |
| Shares Outstanding (Basic) | 202.54M |
| Shares Outstanding (Diluted) | 207.51M |
Key Highlights
- 1Completed the significant acquisition of CareFusion for approximately $12.5 billion in March 2015, creating a combined entity with a leading position in medication management and patient safety.
- 2Reported a 21.7% increase in worldwide revenues to $10.282 billion, primarily due to the inclusion of CareFusion's sales for the latter half of the fiscal year.
- 3The Medical segment saw substantial revenue growth (41.3%) driven by the CareFusion acquisition, while the Life Sciences segment experienced a slight revenue decrease of 1.3%.
- 4Invested $632 million in Research and Development (R&D), an increase from prior years, with a notable portion attributed to the CareFusion integration.
- 5Total debt significantly increased to $11.370 billion at year-end 2015, up from $3.768 billion in 2014, reflecting the financing of the CareFusion acquisition.
- 6The company maintained its dividend payments, distributing $485 million in fiscal year 2015, while suspending its share repurchase program.
- 7Operating income decreased by 33.1% to $1.074 billion in 2015 compared to $1.606 billion in 2014, largely due to acquisition-related costs and purchase accounting adjustments.